144 related articles for article (PubMed ID: 3098401)
1. Factor VIII concentrate for hemophilia: comparison of two heat-treated products.
Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH
CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of a new factor VIII concentrate in hemophilic children].
Carnelli V; Cultrera S; Simoni L; Pasqui G; Busso B; Bagnato L
Pediatr Med Chir; 1983; 5(3):49-55. PubMed ID: 6417627
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
4. Lyophilized cryoprecipitate for children with hemophilia A.
Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
[TBL] [Abstract][Full Text] [Related]
5. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
6. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
Weippert M; Anders O; Schmidt M; Roewer J
Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
[TBL] [Abstract][Full Text] [Related]
8. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
[TBL] [Abstract][Full Text] [Related]
9. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
DiMichele DM; Lasak ME; Miller CH
Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
11. Report of a clinical trial of a Canadian preparation of antihemophilic factor.
Magnin AA; Johnson SE
Can Med Assoc J; 1979 Aug; 121(4):422-4, 427. PubMed ID: 466616
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of factor VIII for surgery and major bleeding.
Hay CR; Doughty HI; Savidge GF
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
[TBL] [Abstract][Full Text] [Related]
13. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
[TBL] [Abstract][Full Text] [Related]
14. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
Toolis F; McKay G; Prowse CV
Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
[TBL] [Abstract][Full Text] [Related]
15. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
[TBL] [Abstract][Full Text] [Related]
16. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
[TBL] [Abstract][Full Text] [Related]
17. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
[TBL] [Abstract][Full Text] [Related]
18. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
[TBL] [Abstract][Full Text] [Related]
19. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.
Remis RS; O'Shaughnessy MV; Tsoukas C; Growe GH; Schechter MT; Palmer RW; Lawrence DN
CMAJ; 1990 Jun; 142(11):1247-54. PubMed ID: 2111726
[TBL] [Abstract][Full Text] [Related]
20. [Results of in vivo analysis of injected fibrinogen degradation products and factor VIII in patients with hemophilia A].
Kätzel R; Kubel M; Scheel H; Wegner H
Z Gesamte Inn Med; 1978 Aug; 33(15):525-9. PubMed ID: 695793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
